Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015
The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…
Biosimilars Advisory Service : Physician Perspectives on Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology | US | 2015
In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…
U.S. Clinician and Payer Receptivity to Immune Checkpoint Inhibitors in Oncology | Physician & Payer Forum | US | 2015
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
The Burgeoning Prostate Cancer Market in the EU5 | Physician & Payer Forum | EU5 | 2015
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
The Battle Between Angiogenesis and EGFR Inhibitors in Colorectal Cancer | Physician & Payer Forum | EU5 | 2015
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…
Novel Combination Strategies in Oncology: Challenges and Opportunities for Developers
Cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly competitive markets is growing. Given the complexity of the multiple pathways and aberrant…
Non-Small-Cell Lung Cancer (The Dynamic NSCLC Market: How Will European Payer and Physician Attitudes Shape This Highly Lucrative Market?) | Physician & Payer Forum | EU5 | 2015
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Ovarian and Endometrial Cancers (Managed Care Insights) | Physician & Payer Forum | US | 2015
Impact of Specialty Pharmacy, Site of Care, and Practice Ownership on Physician Behavior Chemotherapy dominates treatment of both ovarian cancer and endometrial cancer, although Avastin, a…
